Story thread · 2 reports / 2 sources
AbCellera stock surges after menopause drug shows strong trial results
qz.com · 11h · first report
A single dose of ABCL635 cut hot flash frequency by 83% after four weeks, compared with 33% for placebo
The coverage
- AbCellera launches $200-million equity offering on heels of strong menopause trial results
theglobeandmail.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.